Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01897896 · ClinicalTrials.gov registry record · Phase 3
Alternatives for Reducing Chorea in Huntington Disease
A Phase 3 study, sponsored by Auspex Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT01897896 is a Phase 3 study that has completed, run by Auspex Pharmaceuticals. The registered enrollment target is 119 participants.
The verdict
NCT01897896, a Phase 3 study, has completed, sponsored by Auspex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.
Interventions
- DRUG SD-809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2013-11-12 |
| Est. Completion | 2017-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01897896
The ClinicalTrials.gov registry entry for NCT01897896 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auspex Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SD-809 is the first listed.
NCT01897896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01897896 about?
NCT01897896 is a clinical study titled "Alternatives for Reducing Chorea in Huntington Disease". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants ...
What is the current status of trial NCT01897896?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2013-11-12. Estimated completion is 2017-08-21.
What interventions are being tested in trial NCT01897896?
The interventions under investigation include: SD-809 (DRUG).
Who is sponsoring clinical trial NCT01897896?
This trial is sponsored by Auspex Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.